BACKGROUND: NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial. METHODS:Immunity was measured in 28 patients with resected NY-ESO-1-expressing tumours (melanoma 25, breast 3) 252-1,155 days (median = 681) after vaccination. In the earlier vaccination, trial patients received NY-ESO-1 with ISCOMATRIX™ adjuvant at three protein doses 10 μg, 30 μg or 100 μg (n = 14); 100 μg NY-ESO-1 protein (n = 8) or placebo (n = 6), together with 1 μg of intradermal (ID) NY-ESO-1 protein twice for DTH skin testing. Immune responses assessed in the current study included antibody titres, circulating NY-ESO-1-specific T cells and DTH reactivity 2 days after DTH skin testing with NY-ESO-1 protein (1 μg) or peptides (10 μg). Relapse-free survival was determined for 42 melanoma patients. On relapse NY-ESO-1 and HLA, class I was assessed by immunohistochemistry in 17. RESULTS: Persisting anti-NY-ESO-1 immunity was detected in 10/14 recipients who had previously received vaccine with ISCOMATRIX™ adjuvant. In contrast, immunity only persisted in 3/14 who received 100 μg un-adjuvanted NY-ESO-1 protein (3/8) or 2 μg DTH protein (0/6) P = 0.02. Hence, persisting NY-ESO-1 immunity was associated with prior adjuvant. Tumour NY-ESO-1 or HLA class I was downregulated in participants who relapsed suggesting immunoediting had occurred. CONCLUSION: Immunoediting suggests that a signal of anti-tumour activity was observed in high-risk resected melanoma patients vaccinated with NY-ESO-1/ISCOMATRIX™. This was associated with measurable persisting immunity in the majority of vaccinated subjects tested. A prospective randomised trial has been undertaken to confirm these results.
RCT Entities:
BACKGROUND:NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial. METHODS: Immunity was measured in 28 patients with resected NY-ESO-1-expressing tumours (melanoma 25, breast 3) 252-1,155 days (median = 681) after vaccination. In the earlier vaccination, trial patients received NY-ESO-1 with ISCOMATRIX™ adjuvant at three protein doses 10 μg, 30 μg or 100 μg (n = 14); 100 μg NY-ESO-1 protein (n = 8) or placebo (n = 6), together with 1 μg of intradermal (ID) NY-ESO-1 protein twice for DTH skin testing. Immune responses assessed in the current study included antibody titres, circulating NY-ESO-1-specific T cells and DTH reactivity 2 days after DTH skin testing with NY-ESO-1 protein (1 μg) or peptides (10 μg). Relapse-free survival was determined for 42 melanomapatients. On relapse NY-ESO-1 and HLA, class I was assessed by immunohistochemistry in 17. RESULTS: Persisting anti-NY-ESO-1 immunity was detected in 10/14 recipients who had previously received vaccine with ISCOMATRIX™ adjuvant. In contrast, immunity only persisted in 3/14 who received 100 μg un-adjuvanted NY-ESO-1 protein (3/8) or 2 μg DTH protein (0/6) P = 0.02. Hence, persisting NY-ESO-1 immunity was associated with prior adjuvant. TumourNY-ESO-1 or HLA class I was downregulated in participants who relapsed suggesting immunoediting had occurred. CONCLUSION: Immunoediting suggests that a signal of anti-tumour activity was observed in high-risk resected melanomapatients vaccinated with NY-ESO-1/ISCOMATRIX™. This was associated with measurable persisting immunity in the majority of vaccinated subjects tested. A prospective randomised trial has been undertaken to confirm these results.
Authors: Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso Journal: Semin Immunol Date: 2017-10-09 Impact factor: 11.130
Authors: Foluso O Ademuyiwa; Wiam Bshara; Kristopher Attwood; Carl Morrison; Stephen B Edge; Adam R Karpf; Smith A James; Christine B Ambrosone; Tracey L O'Connor; Ellis G Levine; Anthony Miliotto; Erika Ritter; Gerd Ritter; Sacha Gnjatic; Kunle Odunsi Journal: PLoS One Date: 2012-06-28 Impact factor: 3.240
Authors: Cesar Tovar; Ruth J Pye; Alexandre Kreiss; Yuanyuan Cheng; Gabriella K Brown; Jocelyn Darby; Roslyn C Malley; Hannah V T Siddle; Karsten Skjødt; Jim Kaufman; Anabel Silva; Adriana Baz Morelli; Anthony T Papenfuss; Lynn M Corcoran; James M Murphy; Martin J Pearse; Katherine Belov; A Bruce Lyons; Gregory M Woods Journal: Sci Rep Date: 2017-03-09 Impact factor: 4.379
Authors: Katherine Woods; Ashley J Knights; Matthew Anaka; Ralf B Schittenhelm; Anthony W Purcell; Andreas Behren; Jonathan Cebon Journal: J Immunother Cancer Date: 2016-02-16 Impact factor: 13.751
Authors: Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths Journal: Epigenetics Date: 2015 Impact factor: 4.861